Letolizumab
Humanized (from mouse) | |
---|---|
Target | tumor necrosis factor-related activation protein |
Clinical data | |
Other names | BMS-986004 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C1734H2688N466O538S10 |
Molar mass | 38991.90 g·mol−1 |
Letolizumab (
INN;[1] development code BMS-986004) is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.[2]
This drug was developed by
Bristol-Myers Squibb.[3]
References
- ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
- PMID 31119094.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Letolizumab, American Medical Association.